Amgen Inc. or Supernus Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?

SG&A Cost Management: Amgen Inc. vs. Supernus Pharmaceuticals, Inc.

In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Amgen Inc. and Supernus Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management. Amgen, a biotech giant, consistently reported higher SG&A expenses, peaking at approximately $6.2 billion in 2023. This reflects a strategic investment in expansive operations and marketing. In contrast, Supernus Pharmaceuticals, a smaller player, maintained a leaner SG&A structure, with expenses reaching around $336 million in 2023, a mere 5% of Amgen's costs. Over the decade, Amgen's SG&A expenses grew by about 31%, while Supernus saw a staggering 364% increase, indicating aggressive scaling. This data highlights the diverse strategies in SG&A management, with Amgen focusing on scale and Supernus on growth efficiency.